We are live on ! Find out more
TARA icon

Protara Therapeutics
TARA

29 hedge funds and large institutions have $12.3M invested in Protara Therapeutics in 2023 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 7 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 29 → 29 (0)

0% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 3

3.24% less ownership

Funds ownership: 48.66% → 45.42% (-3.2%)

27% less capital invested

Capital invested by funds: $16.9M → $12.3M (-$4.62M)

29% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 7

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
29
Holders Change
–
Holders Change %
0%
% of All Funds
0.46%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
3
Increased
5
Reduced
7
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Renaissance Technologies
Renaissance Technologies
New York
+$73.4K
2
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
+$34.8K
3
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$9.86K
4
TRCT
Tower Research Capital (TRC)
New York
+$6.57K
5
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$5.7K

Top Sellers

1
PA
Perceptive Advisors
New York
-$908K
2
Morgan Stanley
Morgan Stanley
New York
-$183K
3
Citadel Advisors
Citadel Advisors
Florida
-$107K
4
O
OrbiMed
New York
-$62.3K
5
Millennium Management
Millennium Management
New York
-$5.27K
Name Holding Trade Value Shares
Change 		Change in
Stake
OM
1
Opaleye Management
Massachusetts
$6.44M – – –
O
2
OrbiMed
New York
$1.85M -$62.3K -20,974 -3%
Vanguard Group
3
Vanguard Group
Pennsylvania
$1.02M – – –
BC
4
Boxer Capital
California
$500K – – –
BBA
5
Baker Bros. Advisors
New York
$477K – – –
IC
6
Ikarian Capital
Texas
$451K – – –
PFMU
7
Privium Fund Management (UK)
United Kingdom
$272K – – –
Renaissance Technologies
8
Renaissance Technologies
New York
$200K +$73.4K +24,694 +42%
Geode Capital Management
9
Geode Capital Management
Massachusetts
$199K – – –
BCM
10
Bridgeway Capital Management
Texas
$153K – – –
BlackRock
11
BlackRock
New York
$86.6K -$2.54K -854 -2%
Two Sigma Investments
12
Two Sigma Investments
New York
$83K -$2.97K -1,000 -3%
Two Sigma Advisers
13
Two Sigma Advisers
New York
$74.8K -$891 -300 -0.9%
State Street
14
State Street
Massachusetts
$73.9K – – –
Assenagon Asset Management
15
Assenagon Asset Management
Luxembourg
$69.4K +$34.8K +11,715 +68%
Millennium Management
16
Millennium Management
New York
$58.7K -$5.27K -1,773 -7%
Northern Trust
17
Northern Trust
Illinois
$49.2K – – –
BFM
18
Boothbay Fund Management
New York
$45.1K – – –
Dimensional Fund Advisors
19
Dimensional Fund Advisors
Texas
$44.8K +$5.7K +1,918 +11%
Bank of New York Mellon
20
Bank of New York Mellon
New York
$42.8K – – –
Citadel Advisors
21
Citadel Advisors
Florida
$23.9K -$107K -36,179 -78%
LPL Financial
22
LPL Financial
California
$23.9K -$74 -25 -0.2%
Acadian Asset Management
23
Acadian Asset Management
Massachusetts
$15K – – –
Royal Bank of Canada
24
Royal Bank of Canada
Ontario, Canada
$8K +$9.86K +3,320 +3,320%
TRCT
25
Tower Research Capital (TRC)
New York
$5.28K +$6.57K +2,211 New
1
2

TARA Hedge Fund Activity: Q2 2023 in Review

29 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Protara Therapeutics (TARA) for Q2 2023, worth a combined $12.3M — down 27% from $16.9M a quarter earlier.

Fund positioning in TARA was balanced in Q2 2023: 3 funds opened new positions, 3 closed out, 5 added to existing stakes and 7 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $73.4K. The largest seller was Perceptive Advisors, exiting entirely with an estimated $908K sold.

  • 29 institutional investors held Protara Therapeutics (TARA) as of Q2 2023, unchanged from Q1 2023.
  • Funds reported $12.3M of Protara Therapeutics stock for Q2 2023, down 27% quarter-over-quarter.
  • 3 funds opened new Protara Therapeutics positions in Q2 2023 and 3 closed out, a net change of 0 holders.
  • The largest Protara Therapeutics buyer in Q2 2023 was Renaissance Technologies, an estimated $73.4K added.
  • The largest Protara Therapeutics seller in Q2 2023 was Perceptive Advisors, an estimated $908K sold.

Based on aggregated 13F filings for Q2 2023.